Fenfluramine Hydrochloride

FINTEPLA is approved by the U.S. Food and Drug Administration (FDA) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS) in patients two years of age and older.¹ Post hoc analysis of patients with LGS, transitioning from the randomized controlled trial to an open-label extension study, who started FINTEPLA following placebo and those who continued with FINTEPLA showed rapid improvement in seizure frequency and global functioning.² Rapid clinical improvement in seizure frequency and global functioning were observed in both groups, as mean Fintepla dose was increased.² Safety findings were consistent with known data, with expected increases in common adverse events following FINTEPLA initiation and decreasing incidence over time with continued treatment.² These results showed that sustained FINTEPLA treatment is effective and tolerable.² ATLANTA, Aug. 5, 2026 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced that EpilepsiaOpen published findings from a post hoc analysis of trajectories of FINTEPLA effectiveness and safety, along with dose changes over time. The analysis demonstrated sustained improvements in seizure-related outcomes, including rapid improvements in seizure frequency and CGI-I-assessed global functioning following FINTEPLA in children and adults with Lennox-Gastaut syndrome (LGS), like improvements in global functioning (overall improvement beyond seizures) after treatment initiation.² Continue Reading FINTEPLA® (fenfluramine) is approved by the U.S. Food and Drug Administration (FDA) for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome in patients two years of age and older. The analysis included data from patients treated with FINTEPLA who completed an open-label extension (OLE) after receiving either FINTEPLA or placebo during the initial Phase 3, 14-week randomized controlled trial (RCT). Study participants who transitioned from placebo to FINTEPLA in the OLE experienced reduction in seizure frequency and global functioning improvement as early as one month after treatment initiation, with further reductions observed in subsequent months as the mean dose increased. This outcome was consistent with patients treated with FINTEPLA from the start. "LGS remains one of the most challenging rare epilepsies to manage, and families and clinicians often have limited visibility into what response may look like in the first months of treatment," said Hugo Xi, MD, MBA, Head of Medical for Epilepsy and Rare Syndromes at UCB. "These findings provide important insight into the treatment trajectory of FINTEPLA, helping inform conversations around early response, dose titration, and the potential value of continued treatment over time." Highlights from the post hoc analysis² Of 263 patients enrolled in the RCT, 247 (93.9%) continued into the OLE. Of those, 151 (61.1%) completed 12 months of FINTEPLA treatment in the OLE and were included in the post hoc analysis. The analysis evaluated changes over time in the number of seizures associated with a fall, clinically meaningful improvement (defined as "much improved" or "very much improved") on the Clinical Global Impression–Improvement (CGI-I) scale as assessed by parent/caregiver and investigator, and adverse events in two groups: patients randomized to placebo in the RCT who switched to FINTEPLA in the OLE (PBO-FFA; n=59), and those who received FINTEPLA in both the RCT and OLE (FFA-FFA; n=92). Rapid onset of effect: At Month 1 of the OLE, patients in the PBO-FFA group experienced a -32.1% median reduction in seizures associated with a fall compared with baseline. Patients in the FFA-FFA group experienced a -48.5% median reduction. Continued improvement over time: Seizure reductions improved to -48.2% over Months 4-6 in patients in the PBO-FFA group, which was similar to the reductions seen at 4-6 months in the FFA-FFA group (-44.2%). Global functioning improvements: Clinically meaningful improvements in patient global functioning (CGI-I) were observed shortly after patients in the PBO-FFA group initiated FINTEPLA. By Month 12, 52.6% and 46.3% of patients in the PBO-FFA group were rated as demonstrating clinically meaningful improvement by parent/caregiver and investigator, respectively. Similar improvements were observed in the FFA-FFA group, with 50.0% and 50.5% of patients receiving those ratings, respectively. Predictable and well tolerated safety profile: The incidence of most commonly reported treatment-emergent adverse events (TEAEs), including decreased appetite, somnolence, fatigue, diarrhea, pyrexia, and nasopharyngitis, increased in the PBO-FFA group at the time of treatment initiation, as expected. However, the incidence of most commonly reported TEAEs (decreased appetite, somnolence, fatigue, and diarrhea) decreased over time with continued FINTEPLA treatment, suggesting an acceptable long-term tolerability. Note: As these results were obtained in a post hoc analysis, no conclusions of efficacy should be made. For further information, contact UCB: US Communications Becky Malone T +1.919.605.9600 [email protected] Corporate Communications, Media Relations Laurent Schots T +32.2.559.92.64 [email protected] Investor Relations Antje Witte T +32.2.559.94.14 [email protected] About Lennox-Gastaut syndrome (LGS) Lennox-Gastaut syndrome (LGS) is a rare, severe developmental and epileptic encephalopathy (DEE) characterized by the presence of tonic seizures and at least one additional seizure type and severe developmental delays.3 It typically starts during childhood and persists into adulthood.3,4 Approximately 50% of infants with a severe DEE evolve over time to be diagnosed with LGS.3,5 LGS has far-reaching effects beyond seizures; impairments with developmental delay culminating in challenges with cognition, communication, psychiatric symptoms, sleep, behavior, and mobility are common.4 Seizures largely remain drug-resistant into adulthood on currently available medications.4,6 Sudden unexpected death in epilepsy (SUDEP) is a major concern for patients and families with LGS.7 About UCB UCB, Brussels, Belgium () is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 9000 people in approximately 40 countries, the company generated revenue of € 7.7 billion in 2025. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCBUSA. Forward-looking statements This document contains forward-looking statements, including, without limitation, statements containing the words "potential", "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will", "continue" and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management. All statements, other than statements of historical facts, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, arbitration, political, regulatory or clinical results or practices and other such estimates and results. By their nature, such forward-looking statements are not guaranteeing future performance and are subject to known and unknown risks, uncertainties, and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements contained in this document. Important factors that could result in such differences include but are not limited to: global spread and impacts of wars, pandemics and terrorism, the general geopolitical environment, climate change, changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues, supply chain disruption and business continuity risks; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, product liability claims, challenges to patent protection for products or product candidates, competition from other products including biosimilars or disruptive technologies/business models, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws, and hiring, retention and compliance of its employees. There is no guarantee that new product candidates will be discovered or identified in the pipeline, or that new indications for existing products will be developed and approved. Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans. So far, the complexity of the human body cannot be reproduced in computer models, cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory approval for product marketing has varied in the past and UCB expects similar unpredictability going forward. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to disputes between the partners or may prove to be not as safe, effective or commercially successful as UCB may have believed at the start of such partnership. UCB's efforts to acquire other products or companies and to integrate the operations of such acquired companies may not be as successful as UCB may have believed at the moment of acquisition. Also, UCB or others could discover safety, side effects or manufacturing problems with its products and/or devices after they are marketed. The discovery of significant problems with a product similar to one of UCB's products that implicate an entire class of products may have a material adverse effect on sales of the entire class of affected products. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment, including pricing pressure, political and public scrutiny, customer and prescriber patterns or practices, and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement activities and outcomes. Finally, a breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of UCB's data and systems. Given these uncertainties, the public is cautioned not to place any undue reliance on such forward-looking statements. These forward-looking statements are made only as of the date of this document, and do not reflect any potential impacts from the evolving event or risk as mentioned above as well as any other adversity, unless indicated otherwise. The company continues to follow the development diligently to assess the financial significance of these events, as the case may be, to UCB. UCB expressly disclaims any obligation to update any forward-looking statements in this document, either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations. Indication and Important Safety Information about FINTEPLA ® (fenfluramine) in the US FINTEPLA is indicated for the treatment of seizures associated with Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older. IMPORTANT SAFETY INFORMATION BOXED WARNING: VALVULAR HEART DISEASE and PULMONARY ARTERIAL HYPERTENSION FINTEPLA can cause valvular heart disease and pulmonary arterial hypertension. Echocardiogram assessments are required before, during, and after treatment with FINTEPLA. FINTEPLA is available only through a restricted program called the FINTEPLA REMS. CONTRAINDICATIONS FINTEPLA is contraindicated in patients with hypersensitivity to fenfluramine or any of the excipients in FINTEPLA and with concomitant use, or within 14 days of the administration, of monoamine oxidase inhibitors because of an increased risk of serotonin syndrome. WARNINGS AND PRECAUTIONS Valvular Heart Disease and Pulmonary Arterial Hypertension (see Boxed Warning): FINTEPLA can cause valvular heart disease (VHD) and pulmonary arterial hypertension (PAH). Although no patients receiving FINTEPLA developed VHD or PAH in clinical trials for DS and LGS of up to 3 years in duration, cases of VHD and PAH have been reported during use of FINTEPLA in the postmarketing setting. Because of this risk, cardiac monitoring is required prior to starting treatment, during treatment, and after treatment with FINTEPLA concludes. Cardiac monitoring via echocardiogram can identify evidence of VHD and PAH prior to a patient becoming symptomatic, aiding in early detection of these conditions. Monitoring: Prior to starting treatment, patients must undergo an echocardiogram to evaluate for VHD and PAH. Echocardiograms should be repeated every 6 months, and once 3-6 months post treatment with FINTEPLA. The prescriber must consider the benefits versus the risks of initiating or continuing treatment with FINTEPLA if any of the following signs are observed via echocardiogram: valvular abnormality or new abnormality; VHD indicated by mild or greater aortic regurgitation or moderate or greater mitral regurgitation, with additional characteristics of VHD (e.g., valve thickening or restrictive valve motion); PAH indicated by elevated right heart/pulmonary artery pressure (PASP >35 mm Hg). FINTEPLA REMS (see Boxed Warning): FINTEPLA is available only through a restricted distribution program called the FINTEPLA Risk Evaluation and Mitigation Strategy (REMS). Prescribers must be certified by enrolling in the FINTEPLA REMS. Prescribers must counsel patients receiving FINTEPLA about the risk of VHD and PAH, how to recognize signs and symptoms of VHD and PAH, the need for baseline (pretreatment) and periodic cardiac monitoring via echocardiogram during FINTEPLA treatment, and cardiac monitoring after FINTEPLA treatment. Decreased Appetite and Decreased Weight: FINTEPLA can cause decreases in appetite and weight. Decreases in weight appear to be dose related. Weight should be monitored regularly during treatment with FINTEPLA, and dose modifications should be considered if a decrease in weight is observed. Somnolence, Sedation, and Lethargy: FINTEPLA can cause somnolence, sedation, and lethargy. Other central nervous system depressants, including alcohol, could potentiate these effects of FINTEPLA. Prescribers should monitor patients for somnolence and sedation and should advise patients not to drive or operate machinery until they have gained sufficient experience on FINTEPLA to gauge whether it adversely affects their ability to drive or operate machinery. Suicidal Behavior and Ideation: Antiepileptic drugs (AEDs), including FINTEPLA, increase the risk of suicidal thoughts or behaviors in patients taking these drugs for any indication. Patients treated with an AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behaviors, or any unusual changes in mood or behavior. Withdrawal of Antiepileptic Drugs: As with most AEDs, FINTEPLA should generally be withdrawn gradually because of the risk of increased seizure frequency and status epilepticus. If withdrawal is needed because of a serious adverse reaction, rapid discontinuation can be considered. Serotonin Syndrome: Serotonin syndrome, a potentially life-threatening condition, may occur with FINTEPLA, particularly during concomitant administration of FINTEPLA with other serotonergic drugs, including, but not limited to, selective serotonin-norepinephrine reuptake inhibitors (SNRIs), selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), bupropion, triptans, dietary supplements (e.g., St. John's Wort, tryptophan), drugs that impair metabolism of serotonin (including monoamine oxidase inhibitors [MAOIs], which are contraindicated with FINTEPLA), dextromethorphan, lithium, tramadol, and antipsychotics with serotonergic agonist activity. Patients should be monitored for the emergence of signs and symptoms of serotonin syndrome, which include mental status changes, autonomic instability, neuromuscular signs, and/or gastrointestinal symptoms. If serotonin syndrome is suspected, treatment with FINTEPLA should be stopped immediately and symptomatic treatment should be started. Increase in Blood Pressure: FINTEPLA can cause an increase in blood pressure. Rare cases of significant elevation in blood pressure, including hypertensive crisis, have been reported in adult patients treated with fenfluramine, including patients without a history of hypertension. In clinical trials for DS and LGS of up to 3 years in duration, no pediatric or adult patient receiving FINTEPLA developed hypertensive crisis. Monitor blood pressure in patients treated with FINTEPLA. Glaucoma: Fenfluramine can cause mydriasis and can precipitate angle closure glaucoma. Consider discontinuing treatment with FINTEPLA in patients with acute decreases in visual acuity or ocular pain. ADVERSE REACTIONS The most common adverse reactions observed in DS studies (incidence at least 10% and greater than placebo) were decreased appetite; somnolence, sedation, lethargy; diarrhea; constipation; abnormal echocardiogram; fatigue, malaise, asthenia; ataxia, balance disorder, gait disturbance; blood pressure increased; drooling, salivary hypersecretion; pyrexia; upper respiratory tract infection; vomiting; decreased weight; fall; status epilepticus. The most common adverse reactions observed in the LGS study (incidence at least 10% and greater than placebo) were diarrhea; decreased appetite; fatigue; somnolence; vomiting. To report SUSPECTED ADVERSE REACTIONS, contact UCB, Inc. at 1-844-599-2273 or FDA at 1-800-FDA-1088 or . Please see full Prescribing Information , including Boxed Warning and Medication Guide , for additional Important Safety Information on FINTEPLA. FINTEPLA® is a registered trademark of the UCB Group of Companies. References: FINTEPLA (fenfluramine) oral solution: U.S. prescribing information. Smyrna, GA: UCB, Inc. October 2025. Nabbout R, Devinsky O, Lagae L, et al. Changes in effectiveness and safety in patients with Lennox-Gastaut syndrome transitioning from the fenfluramine randomized controlled trial to open-label extension study. Specchio N, Wirrell EC, Scheffer IE, et al. International League Against Epilepsy classification and definition of epilepsy syndromes with onset in childhood: Position paper by the ILAE Task Force on Nosology and Definitions. Epilepsia. 2022;63(6):1398-1442. NORD. LGS. Available at: . Last accessed: June 2026. Berg AT, Levy SR, Testa FM. Evolution and course of early life developmental encephalopathic epilepsies: Focus on Lennox-Gastaut syndrome. Epilepsia. 2018 ;59(11):2096-2105. LGS Foundation. What is Lennox-Gastaut Syndrome? Available at: . Last accessed: April 2026. LGS Foundation. Sudden Unexpected Death in Epilepsy (SUDEP). Available at: . Last accessed: April 2026. FINTEPLA® is a registered trademark of the UCB Group of Companies. ©2026 UCB, Inc., Smyrna, GA 30080. All rights reserved. US-FA-2600260 SOURCE UCB 21% more press release views with Request a Demo

UCB has presented new data at the American Academy of Neurology Annual Meeting 2026 highlighting the impact of epilepsy on quality of life for both patients and caregivers. The findings include interim survey results in developmental and epileptic encephalopathies (DEEs), showing that more than a quarter of patients experience daily sleep disturbances. These were linked to temporary loss of activities of daily living (ADLs) and communication in a significant proportion of cases. Andrea Wilkinson, UCB Global Head of Patient Engagement and Advocacy and lead author of the study, said: “These results demonstrate the clear relationship between disrupted sleep and temporary losses in daily function and communication, underscoring the importance of addressing disease impacts beyond seizure alone.” Additional real-world data showed that prolonged seizures affect the ability to carry out everyday activities, with 88% of patients and 96% of caregivers reporting disruption. Seizures were also associated with reduced work productivity and increased anxiety and depression among both groups. A subgroup analysis of patients experiencing prolonged seizures found higher use of healthcare resources compared with non-prolonged events, including increased hospitalisations, emergency visits and ambulance use. Separate data presented at the meeting evaluated treatment persistence with fenfluramine in people with Lennox-Gastaut syndrome (LGS) in the USA. The analysis indicated reductions in use of healthcare resources and antiseizure medication burden among patients who remained on treatment. Fenfluramine showed decreases in in-patient hospitalisation claims, emergency room visits and ambulance use among patients for whom there was 12 months of continuous treatment data available. Treatment persistence was reported at 73% at six months and 61% at 12 months. UCB said the findings reflect the broader burden of epilepsy beyond seizure control, including impacts on daily functioning, mental health and healthcare use. “Families living with LGS manage far more than seizures alone. Fewer emergency room visits, hospitalizations, and ambulance use can translate into less disruption, fewer crises and more stability for families,” said UCB Head of US Medical Neurology, Hugo Xi. He added that the ongoing, persistent use of the treatment helped reinforce available evidence that such therapy was compatible with patients’ real-life situations. UCB presented a total of 21 abstracts at the meeting. Two-thirds focussed on epilepsy, with the remainder devoted to rare neurological conditions, including six myasthenia gravis (MG) abstracts.